摘要
目的探讨应用缬沙坦合并疏血通治疗肺心病的临床价值及意义。方法回顾性分析我院2007年1月~2011年1月应用缬沙坦合并疏血通治疗肺心病123例,将其随机分为治疗组和对照组。治疗组63例,在一般治疗的基础上给予缬沙坦80mg/次,1次/d口服,疏血通6mL/次,加5%葡萄糖注射液250mL,1次/d静滴,连用14d;对照组60例,仅给予抗感染、氧疗、控制心力衰竭等一般治疗。结果治疗组有效率74.6%,对照组有效率55%,治疗组与对照组相比,差异有统计学意义(χ2=5.2,P<0.05)。结论应用缬沙坦合并疏血通治疗肺心病有效,能明显改善患者呼吸功能,提高生存率。
Objective To explore the application of valsartan combined with Shuxuetong injection in treatment of pulmonary heart disease clinical value and significance. Methods Retrospective analyzed our hospital in 2007 January to 2011 January application of valsartan combined with Shuxuetong injection in treatment of pulmonary heart disease in 123 cases,which were randomly divided into treatment group and control group. The treatment group 63 examples, based on general treatment,were treated with valsartan 80mg/time,1 times a day,and Shuxuetong 6mL/time,plus 5% dextrose injection 250mL,l times a day of intravenous drip,used 14 days. The control group of 60 cases only underwent the anti-infection,oxygens therapy, heart failure and control general treatment. Results The effective rate of treatment group was 74.6% and control group was 55%,the difference was statistically significant (χ^2=5.2,P〈 0.05). Conclusion Valsartan combined with Shuxuetong injection in treatment of pulmonary heart disease is effective,and can significant improve the respiratory function,increase the survival rate.
出处
《中国现代医生》
2011年第35期136-137,共2页
China Modern Doctor
关键词
缬沙坦
疏血通
肺心病
Valsartan
Shuxuetong
Pulmonary heart disease